# A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

> **NCT04748848** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 1 (actual)

## Conditions studied

- Leukemia, Myeloid

## Interventions

- **DRUG:** CC-90011
- **DRUG:** Venetoclax
- **DRUG:** Azacitidine
- **DRUG:** Venetoclax
- **DRUG:** CC-90011

## Key facts

- **NCT ID:** NCT04748848
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-14
- **Primary completion:** 2022-03-09
- **Final completion:** 2022-03-09
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Business objectives have changed.
- **Last updated:** 2023-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04748848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04748848, "A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04748848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*